EiRx Therapeutics plc (AIM: ERX), the drug discovery company developing targeted therapies for cancer, is pleased to announce that it has entered into a collaboration agreement with bioMérieux SA, the leading international diagnostics group headquartered in Marcy l’Etoile, France. Under the terms of the agreement, the companies will work together to validate the diagnostic and therapeutic potential of candidate tumour markers emerging from their respective cancer research programmes.
